SIG Greatest Hits: TLM 2025-MASLD SIG: MASLD Semaglutide Update

Video Transcription

Video Summary

The ASLD writing group discussed the FDA's accelerated approval of semaglutide (Wegovy) for treating MASH with moderate to advanced fibrosis (F2-F3), based on phase 3 ESSENCE trial data. Semaglutide showed significant histologic improvement in MASH resolution and fibrosis reduction. Patient selection should use liver stiffness (VCTE 8-15 kPa, ELF 9.2-10.5) and exclude cirrhosis, pregnancy, or certain cancers. Safety monitoring includes symptom checks and liver enzyme tests, with attention to pancreatitis and gallstones. Treatment response should be assessed at 72 weeks using non-invasive tests. Lifestyle modification remains essential alongside therapy.

Asset Subtitle

Talk delivered by Dr. Meena Bansal. Talk was part of the American Association for the Study of Liver Diseases Guidelines: What's New in 2025 session.

Keywords

semaglutide

MASH treatment

FDA accelerated approval

ESSENCE trial

liver fibrosis monitoring